MYCOLab Ai Logo - gold and army green

Microbial Fibrinolytic Enzymes as Anti-thrombotics: Production, Characterisation and Prodigious Biopharmaceutical Applications

Summary

This research examines how certain enzymes produced by microorganisms can safely dissolve blood clots and potentially treat cardiovascular diseases. These natural enzymes offer several advantages over traditional blood-thinning medications, including fewer side effects and lower production costs. Impacts on everyday life: • Provides safer alternatives to traditional blood-thinning medications for preventing heart attacks and strokes • Offers potential new treatments for cardiovascular diseases that are more affordable and accessible • Creates opportunities for developing new food supplements that could help prevent blood clots • Enables development of better detergents for removing blood stains from clothing • Demonstrates how natural compounds from fermented foods can have significant health benefits

Background

Cardiac disorders like acute myocardial infarction, embolism and stroke are primarily caused by excessive fibrin accumulation in blood vessels leading to thrombosis. While traditional anti-thrombotic strategies like anti-coagulants and anti-platelet drugs are used, they have undesirable side effects and high costs. Microbial fibrinolytic enzymes have emerged as promising alternatives due to their high efficacy, minimal side effects, and cost-effective production.

Objective

This review aims to comprehensively examine the production, biochemical properties, thrombolytic potential and additional applications of microbial fibrinolytic enzymes. The review covers recent technological advances in enzyme production, characterization methods, structural-functional attributes, and both therapeutic and industrial applications.

Results

The review found that microbial fibrinolytic enzymes can be effectively produced from various bacterial and fungal sources, particularly from fermented foods. Statistical optimization and genetic modification techniques significantly improve enzyme production and activity. Most enzymes show optimal activity at neutral to alkaline pH (7-10) and temperatures of 37-50°C. In vitro and in vivo studies demonstrate their effectiveness in dissolving blood clots with minimal side effects. Beyond thrombolysis, these enzymes show promise in blood pressure regulation, as antimicrobials, and as detergent additives.

Conclusion

Microbial fibrinolytic enzymes represent promising alternatives to traditional thrombolytic agents due to their high specificity, minimal side effects, and cost-effective production. Their diverse applications in therapeutic and industrial sectors warrant further research and development. While challenges remain in understanding certain mechanisms of action, these enzymes show significant potential for treating cardiovascular diseases and other applications.
  • Published in:Pharmaceutics,
  • Study Type:Review,
  • Source: 10.3390/pharmaceutics13111880
Scroll to Top